Empowering Businesses Xentria Inc's Transformative Journey

The Xentria trial is a Phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis. See below for information about the trial sites for this clinical ... Tom Shea Summary. Tom Shea, based in Chicago, IL, US, is currently a Chief Executive Officer at Xentria, Inc.. Tom Shea brings experience from previous roles at ... Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, today announced ... Keymed Biosciences Co.Ltd · Fondazione Policlinico Universitario Agostino Gemelli... Terminado · Xentria, Inc. Terminado · Serum Institute of India ... Xentria, Inc. has partnered with the Foundation for Sarcoidosis Research for the XTMAB16 Study. XTMAB-16 is a tumor necrosis factor (TNF) inhibitor that aims to ... Sponsor: Xentria, Inc. Overall Status: Active - Recruiting. Phase. 1/2. Condition. Sarcoidosis. Lung Disease. Treatment. XTMAB-16 or Placebo ... Xentria - Developer of therapeutics for treating cancer, metabolic diseases & musculoskeletal diseases. Raised a total funding of $25M over 1 round. Xentria, a Chicago, IL-based biotech company, raised $25M in Equity funding. Gale OneFile includes U.S. Clinical Trial: Xentria, Inc. Listed a New Clinica by . Click to explore. Vice President, Clinical Development - Xentria, Inc. · Solutions-focused clinical development professional with a diverse background in patient care, ...